<DOC>
	<DOCNO>NCT00388128</DOCNO>
	<brief_summary>The purpose study evaluate change Walking capacity intake caffeine . The study design cross-over follow-up 80 patient leg pain cause narrowing leg artery , Peripheral Vascular Disease ( PAD ) , stage II . Half revascularised , follow 3 month . It hypothesize caffeine ( 6mg/kg ) cheap , safe drug walk exercise . Primary endpoint maximum walk distance ( MWD ) , treadmill-testing , ( constant load , 0 % ,2m/h ) . Secondary endpoint pain free walking distance ( PWD ) , maximum muscle strength , endurance , reaction speed , balance , cognitive function , health relate quality life ( SF-36 ) .</brief_summary>
	<brief_title>Caffeine Intermittent Claudication</brief_title>
	<detailed_description>PAD prevalence 15-20 % elderly ( &gt; 50 ) western population . PAD see isolation represent peripheral manifestation generalize artherosclerosis . The co-morbidity coronary cerebralartherosclerosis depend degree severity PAD , relative risk death ( predominantly cardiac ) increase factor 4 . From af medical socio-economic point view need control PAD complication rate relate treatment cost effectively possible . The aim treatment intermittent claudication clinically relevant improvement patientÂ´s mobility quality life . There agreement , physical training improve collateralisation vascular lesion , rheologic property blood lead shift glycolytic oxidative muscle fiber work musculature increase capillary density . The effect physical training also modify patient risk factor profile , even moderate training increase insulin receptor sensitivity fibrinolytic activity decrease dLDL/HDL ratio diastolic blood pressure hypertensive patient - thereby decrease overall cardiac mortality . This Phase 3 , 12-week , double-blind , randomize , placebo-controlled cross-over follow-up study 80 patient intermittent claudication , half revascularized . The objective study evaluate efficacy caffeine ( 6mg/kg ) revascularisation procedure . The primary end-point maximal walk distance ( MWD ) group patient . Other efficacy measure include claudication onset time ( PWD ) , change Ankle Brachial Index ( ABI ) , Quality Life ( QoL ) , cognitive function , plasma response Vascular Endothelian Growth Factor ( VEGF , FGF ) . Safety variable include routine hematology parameter adverse event .</detailed_description>
	<mesh_term>Intermittent Claudication</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<criteria>men woman &gt; 40 year history IC low extremity , Fontaine II anklebrachial index ( ABI ) &gt; 0.9 ( subject refer revasularizarition procedure ) dementia diabetes illness reason unable participate , f.ex . general weakness , amputation arthritis acute illness , f.ex . inflammation , unstable angina reason contraindicate participation/treadmill exercise intake Trental and/or Teofyllamin weight &gt; 100kg</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Intermittent Claudication</keyword>
	<keyword>PAD</keyword>
	<keyword>Caffeine</keyword>
	<keyword>Walking capacity</keyword>
	<keyword>ABI</keyword>
	<keyword>QoL</keyword>
	<keyword>Growth factor</keyword>
</DOC>